BartlettD.L., LiuZ., SathaiahM., et al. (2013). Oncolytic viruses as therapeutic cancer vaccines. Mol. Cancer, 12, 103.
2.
ChambersR., GillespieG.Y., SoroceanuL., et al. (1995). Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc. Natl. Acad. Sci. USA, 92, 1411–1415.
3.
ChattopadhyayM., GossJ., WolfeD., et al. (2004). Protective effect of herpes simplex virus-mediated neurotrophin gene transfer in cisplatin neuropathy. Brain, 127, 929–939.
4.
FinkD.J., WechuckJ., MataM., et al. (2011). Gene therapy for pain: results of a phase I clinical trial. Ann. Neurol., 70, 207–212.
5.
FraefelC., JacobyD.R., and BreakefieldX.O. (2000). Herpes simplex virus type 1-based amplicon vector systems. Adv. Virus Res., 55, 425–451.
6.
GloriosoJ.C., and FinkD.J. (2009). Herpes vector-mediated gene transfer in the treatment of chronic pain. Mol. Ther., 17, 13–18.
7.
GloriosoJ.C., MataM., and FinkD.J. (2003). Gene therapy for chronic pain. Curr. Opin. Mol. Ther., 5, 483–488.
8.
GoinsW.F., SternbergL.R., CroenK.D., et al. (1994). A novel latency-active promoter is contained within the herpes simplex virus type 1 UL flanking repeats. J. Virol., 68, 2239–2252.
9.
GoinsW.F., LeeK.A., CavalcoliJ.D., et al. (1999). Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity. J. Virol., 73, 519–532.
10.
GoldinA.L., Sandri-GoldinR.M., LevineM., and GloriosoJ.C. (1981). Cloning of herpes simplex virus type 1 sequences representing the whole genome. J. Virol., 38, 50–58.
11.
GossJ.R., MataM., GoinsW.F., et al. (2001). Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Ther., 8, 551–556.
12.
GossJ.R., HarleyC.F., MataM., et al. (2002). Herpes vector-mediated expression of proenkephalin reduces bone cancer pain. Ann. Neurol., 52, 662–665.
13.
GossJ.R., CascioM., GoinsW.F., et al. (2011). HSV delivery of a ligand-regulated endogenous ion channel gene to sensory neurons results in pain control following channel activation. Mol. Ther., 19, 500–506.
14.
HaoS., MataM., GoinsW., et al. (2003). Transgene-mediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect in neuropathic pain. Pain, 102, 135–142.
15.
HaoS., MataM., WolfeD., et al. (2005). Gene transfer of glutamic acid decarboxylase reduces neuropathic pain. Ann. Neurol., 57, 914–918.
16.
HaoS., MataM., GloriosoJ.C., and FinkD.J. (2007). Gene transfer to interfere with TNFalpha signaling in neuropathic pain. Gene Ther., 14, 1010–1016.
17.
HaoS., WolfeD., GloriosoJ.C., et al. (2009). Effects of transgene-mediated endomorphin-2 in inflammatory pain. Eur. J. Pain, 13, 380–386.
18.
HobbsW.E., BroughD.E., KovesdiI., and DeLucaN.A. (2001). Efficient activation of viral genomes by levels of herpes simplex virus ICP0 insufficient to affect cellular gene expression or cell survival. J. Virol., 75, 3391–3403.
LynaghT., and LynchJ.W. (2010). An improved ivermectin-activated chloride channel receptor for inhibiting electrical activity in defined neuronal populations. J. Biol. Chem., 285, 14890–14897.
21.
MarconiP., KriskyD., OliginoT., et al. (1996). Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc. Natl. Acad. Sci. USA, 93, 11319–11320.
22.
MarconiP., TamuraM., MoriuchiS., et al. (2000). Connexin 43-enhanced suicide gene therapy using herpesviral vectors. Mol. Ther., 1, 71–81.
23.
MarkertJ.M., LiechtyP.G., WangW., et al. (2009). Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol. Ther., 17, 199–207.
24.
McGeochD.J. (1987). The genome of herpes simplex virus: structure, replication and evolution. J. Cell Sci. Suppl., 7, 67–94.
25.
McGeochD.J., DalrympleM.A., DavisonA.J., et al. (1988). The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. J. Gen. Virol., 69 (Pt 7), 1531–1574.
26.
MinetaT., RabkinS.D., YazakiT., et al. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med., 1, 938–943.
27.
MoriuchiS., OliginoT., KriskyD., et al. (1998). Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-alpha and herpes simplex virus thymidine kinase. Cancer Res., 58, 5731–5737.
28.
OmuraS. (2008). Ivermectin: 25 years and still going strong. Int. J. Antimicrob. Agents, 31, 91–98.
29.
PalellaT.D., HidakaY., SilvermanL.J., et al. (1989). Expression of human HPRT mRNA in brains of mice infected with a recombinant herpes simplex virus-1 vector. Gene, 80, 137–144.
30.
PerryL.J., and McGeochD.J. (1988). The DNA sequences of the long repeat region and adjoining parts of the long unique region in the genome of herpes simplex virus type 1. J. Gen. Virol., 69 (Pt 11), 2831–2846.
31.
SamaniegoL.A., WuN., and DeLucaN.A. (1997). The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. J. Virol., 71, 4614–4625.
32.
ShepardA.A., and DeLucaN.A. (1991). A second-site revertant of a defective herpes simplex virus ICP4 protein with restored regulatory activities and impaired DNA-binding properties. J. Virol., 65, 787–795.
33.
SimonatoM., BennettJ., BoulisN.M., et al. (2013). Progress in gene therapy for neurological disorders. Nat. Rev. Neurol., 9, 277–291.
34.
SpaeteR.R., and FrenkelN. (1985). The herpes simplex virus amplicon: analyses of cis-acting replication functions. Proc. Natl. Acad. Sci. USA, 82, 694–698.
35.
SrinivasanR., HuangS., ChaudhryS., et al. (2007). An HSV vector system for selection of ligand-gated ion channel modulators. Nat. Methods, 4, 733–739.
36.
StevensJ.G. (1987). Defining herpes simplex genes involved in neurovirulence and neuroinvasiveness. Curr. Eye Res., 6, 63–67.
37.
UchidaH., MarzulliM., NakanoK., et al. (2013). Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Mol. Ther., 21, 561–569.
38.
WilsonS.P., YeomansD.C., BenderM.A., et al. (1999). Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc. Natl. Acad. Sci. USA, 96, 3211–3216.
39.
WolfeD., CraftA.M., CohenJ.B., and GloriosoJ.C. (2010). A herpes simplex virus vector system for expression of complex cellular cDNA libraries. J. Virol., 84, 7360–7368.
40.
WuC.A., NelsonN.J., McGeochD.J., and ChallbergM.D. (1988). Identification of herpes simplex virus type 1 genes required for origin-dependent DNA synthesis. J. Virol., 62, 435–443.
41.
YaoF., and SchafferP.A. (1995). An activity specified by the osteosarcoma line U2OS can substitute functionally for ICP0, a major regulatory protein of herpes simplex virus type 1. J. Virol., 69, 6249–6258.
42.
ZaupaC., Revol-GuyotV., and EpsteinA.L. (2003). Improved packaging system for generation of high-level noncytotoxic HSV-1 amplicon vectors using Cre-loxP site-specific recombination to delete the packaging signals of defective helper genomes. Hum. Gene Ther., 14, 1049–1063.
